We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Neuralstem Enters into Clinical Trial Research Agreement with University of Pennsylvania
News

Neuralstem Enters into Clinical Trial Research Agreement with University of Pennsylvania

Neuralstem Enters into Clinical Trial Research Agreement with University of Pennsylvania
News

Neuralstem Enters into Clinical Trial Research Agreement with University of Pennsylvania

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Neuralstem Enters into Clinical Trial Research Agreement with University of Pennsylvania"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Neuralstem, Inc. has announced that it has entered into a Clinical Trial Research Agreement aimed at treating patients suffering from Ischemic Spastic Paraplegia, a form of spinal cord paralysis, with the Trustees of the University of Pennsylvania through its Department of Anesthesiology and Critical Care.

The Institution's Principal Investigator is Dr. Albert Cheung, Department of Anesthesiology, Hospital of the University of Pennsylvania.

"We are extremely pleased to be partnering with the University of Pennsylvania Hospital, and Dr. Cheung's team on this important milestone," said Neuralstem President & CEO Richard Garr. "They bring world class experience and talent across the many disciplines that are required for moving into the clinic for our first human trial."

"We at Penn are deeply committed to finding a way to help these patients, and we are excited to be working with Neuralstem's cutting-edge technology," commented Dr. Cheung.

"I am proud to lead this very experienced team that is already at work tackling the important and exciting challenges we face in creating a safe and effective protocol for the first human trials."

Ischemic Spastic Paraplegia (ISP) is a painful form of extreme spasticity and rigidity that causes permanent and untreatable loss of motor function and paralysis. ISP can result from surgery to repair aortic aneurysms, an operation that is performed on thousands of patients each year around the world.

Advertisement